Kaftrio

Developed for: cystic fibrosis · cystic fibrosis-related liver disease
Investigated by: Amsterdam UMC · Cystic Fibrosis Registry of Ireland · Erasmus Medical Center · Imperial College London · Medizinische Hochschule Brandenburg Theodor Fontane · Queen's University, Belfast
+6 more
· Royal College of Surgeons, Ireland · St. James's Hospital, Ireland · Teagasc · The Hospital for Sick Children · University College Dublin · University of Limerick

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Approved	EU (EMA)	Kaftrio	—	2020-08-21	europa.eu ↗

today

EU approved 2020

NCT04602468 · Ph 4

202120222023202420252026202720282029

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 4	NCT04602468	Sep 2020 → Apr 2029 expected	cystic fibrosis, cystic fibrosis-related liver disease	Royal College of Surgeons, Ireland	Active not recruiting	Met primary

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	Kaftrio	ClinicalTrials.gov intervention name — accepted as the source's own label NCT04602468 ↗